7 October 2016 - Health insurer Anthem said it will not cover Sarepta Therapeutics Inc's medicine to treat patients with the rare condition of Duchenne muscular dystrophy (DMD), calling it "investigational and not medically necessary."

The U.S. FDA approved the medicine last month under pressure from patient advocates, even though an outside panel of experts and the agency's own reviewers had questioned its efficacy.

Sarepta has priced the medicine, called Exondys 51, at about $300,000 per patient per year.

Read Reuters article